Investigational drug · Phase 2
BL0175
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Breast Cancer (Locally Advanced or Metastatic).
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "BL0175"
First trial start
2026
Sep 9, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BL0175", any sponsor or status.
Conditions studied
As listed on its trial records.
- Breast Cancer (Locally Advanced or Metastatic)
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "BL0175" as an intervention, largest first.
Shanghai Best-Link Bioscience, LLCIndustry
NCT07658183 · 120 participants (planned) · Start Sep 9, 2026 · Primary completion Oct 31, 2027
Drug: BL0175 Injection; BL0175 Injection · For: Breast Cancer (Locally Advanced or Metastatic)
Sites: Shanghai, China
- A Study of Single Dose of BL0175 in Postmenopausal WomenNot yet recruiting
Shanghai Best-Link Bioscience, LLCIndustry
NCT07366632 · 27 participants (planned) · Start Jan 26, 2026 · Primary completion May 8, 2026
Drug: BL0175; Fulvestrant · For: Postmenopausal Women
Shanghai Best-Link Bioscience, LLCIndustry
NCT06738966 · 9 participants (planned) · Start Mar 10, 2025 · Primary completion Feb 20, 2026
Drug: BL0175 · For: Breast Cancer; Ovarian Cancer; Endometrial Cancer
Sites: Changchun, China; Jinan, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Breast Cancer (Locally Advanced or Metastatic)
- Dual-target CAR-NK cellsEB-DT-CAR-NK, Essen Biotech Dual-Target CAR-NKPhase 25 trials
Beijing Biotech · HER2-positive Breast Cancer, Non-Small Cell Lung Cancer, Breast Cancer (Locally Advanced or Metastatic)
- GB268Phase 21 trial
Eddingpharm (Zhuhai) Co., Ltd. · Breast Cancer (Locally Advanced or Metastatic)
- INV-6452Phase 21 trial
Shenzhen Ionova Life Sciences Co., Ltd. · Breast Cancer (Locally Advanced or Metastatic), Advanced Solid Cancers, Metastatic (Stage IV) Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.